Eli Lilly and Company (LLY)
Investing in This Healthcare Stock Could Be Like Catching Nvidia at the Dawn of the AI Boom
Since ChatGPT was released almost two years ago, shares of Nvidia have soared over 500%. Outside of the tech sector, new diabetes and obesity treatments have revved up the pharma space.
Eli Lilly Is Finally Cheap, Warranting An Upgrade To Buy
Eli Lilly's long-term growth prospects have been secured by the improved supply in H2'24 and the incoming capacity additions from H1'25 onwards. This is on top of the introduction of its D2C channel for self-pay patients, with it offering the company a new growth opportunity through the uninsured patients. This is also why LLY does not appear to be expensive at current levels, with the FWD PEG non-GAAP ratio of 1.30x, well below its historical levels and sector peers.
Prediction: This Is What Eli Lilly Stock Will Do Next (Hint: It's Not a Stock Split)
Eli Lilly has become a household name thanks to breakthrough diabetes and obesity care medicines. The stock has trounced the broader market over the past year, and shares have become a bit pricey.
Eli Lilly: I Admit Defeat As I Understated Its Growth Prospects (Upgrade)
Eli Lilly has proved me wrong again, outperforming the S&P 500 since my previous update. Lilly is gaining share and achieving breakthroughs in the US commercial market. Its pipeline is growing, potentially expanding the treatment areas and bolstering its TAM.
Prediction: This Will Be the Biggest Pharma Stock in 10 Years
24/7 Wall St. Insights Eli Lilly and Co. (NYSE: LLY) is the clear frontrunner to be the largest pharmaceutical stock in 2034.
1 Unstoppable Stock That Could Join the $1 Trillion Club in 2025
Most of the stocks in the trillion-dollar club are tech stocks. One of the biggest names in healthcare, Eli Lilly, could join those ranks within the next few months.
Prediction: This Will be Eli Lilly's Next Big Move.
Eli Lilly's stock has climbed almost 60% this year and trades for more than $900. The pharma giant also has seen soaring sales thanks to its dominance in the high-growth weight loss drug market.
Eli Lilly Stock Up 21% in 6 Months: Time to Add to Your Portfolio?
Investors can buy LLY stock based on its strong overall financial performance and robust drug pipeline.
Prediction: This Will Be the First Healthcare Stock to Join the Trillion-Dollar Club
A huge opportunity in healthcare today is treatment of patients for diabetes and obesity. Another emerging area with limited competition is treating Alzheimer's disease.
Is Most-Watched Stock Eli Lilly and Company (LLY) Worth Betting on Now?
Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Lilly Gets FDA Approval for Eczema Drug Ebglyss
The FDA approves Lilly's Ebglyss based on data from ADvocate 1, ADvocate 2 and ADhere studies.
US FDA approves Eli Lilly's eczema drug
Eli Lilly said on Friday the U.S. Food and Drug Administration approved its eczema drug for use in adults and children above 12 years old.
